Charles River completed the acquisition of MPI research for $800m.

Charles River Laboratories International, a provider of essential products and services to help pharmaceutical and biotechnology companies completed the acquisition of MPI Research, a premier non-clinical contract research organization (CRO) providing comprehensive testing services to biopharmaceutical and medical device companies worldwide for $800m. Acquiring MPI will enhance Charles River’s position as a leading global early-stage CRO by strengthening its ability to partner with clients across the drug discovery and development continuum. “We are pleased to welcome the exceptional team at MPI Research to the Charles River family. The addition of MPI’s scientific expertise, high-quality services, and complementary capabilities will enable us to enhance the support we can provide to clients," James C. Foster, Charles River Laboratories Chairman, and Chief Executive Officer.